Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activities
Growth Metrics
Income Statement
Others
Ratios

Acro Biomedical (ACBM) Change in Accured Expenses (2016 - 2025)

Acro Biomedical (ACBM) has 10 years of Change in Accured Expenses data on record, last reported at -$1315.0 in Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 25.6% year-over-year to -$1315.0; the TTM value through Dec 2025 reached -$36878.0, down 230587.5%, while the annual FY2025 figure was -$36878.0, 230587.5% down from the prior year.
  • Change in Accured Expenses reached -$1315.0 in Q4 2025 per ACBM's latest filing, down from $23404.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $65500.0 in Q3 2023 and bottomed at -$47685.0 in Q2 2025.
  • Average Change in Accured Expenses over 5 years is $4353.8, with a median of $442.0 recorded in 2024.
  • Peak YoY movement for Change in Accured Expenses: skyrocketed 1010.17% in 2023, then plummeted 10888.46% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at $4000.0 in 2021, then soared by 1291.78% to $55671.0 in 2022, then crashed by 97.47% to $1408.0 in 2023, then tumbled by 174.36% to -$1047.0 in 2024, then dropped by 25.6% to -$1315.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were -$1315.0 in Q4 2025, $23404.0 in Q3 2025, and -$47685.0 in Q2 2025.